← Back to Search

Checkpoint Inhibitor

PV-10 + Pembrolizumab for Melanoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Provectus Biopharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Stage IV or Stage III (unresectable, in-transit or satellite) melanoma
At least 1 Injectable Lesion suitable for injection with PV-10
Must not have
Prior treatment with PV-10 or any checkpoint inhibitor without meeting specific criteria
Subjects unable to comprehend and give informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months from initiation of study treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing PV-10, a new cancer treatment, in combination with an existing cancer treatment, pembrolizumab, to see if it is effective in treating metastatic melanoma.

Who is the study for?
Adults with confirmed melanoma, either Stage IV or unresectable Stage III, who have at least one lesion that can be treated with an injection and are fit for pembrolizumab therapy. They must not be pregnant, should use effective contraception if of childbearing potential, and cannot have untreated brain metastases or a history of severe autoimmune disease.
What is being tested?
The trial is testing PV-10 in combination with Pembrolizumab versus Pembrolizumab alone for treating metastatic melanoma. Initially, all participants will receive both treatments; later on, they'll be randomly assigned to continue this combo or just get Pembrolizumab.
What are the potential side effects?
Potential side effects include reactions at the injection site from PV-10 and immune-related issues such as inflammation in organs due to Pembrolizumab. Other common side effects may involve fatigue, skin problems, digestive disturbances and changes in blood tests.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My melanoma is at an advanced stage and cannot be surgically removed.
Select...
I have at least one tumor that can be injected.
Select...
My melanoma diagnosis was confirmed through lab tests.
Select...
I am fully active or can carry out light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have not been treated with PV-10 or checkpoint inhibitors without meeting certain conditions.
Select...
I am unable to understand and agree to the study's details.
Select...
I have melanoma that has spread to my brain and it's either untreated or still active.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months from initiation of study treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months from initiation of study treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change in immune biomarkers
Objective Response Rate (ORR)
Overall Survival (OS)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Phase 2 (Arm 1)Experimental Treatment2 Interventions
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Group II: Phase 1bExperimental Treatment2 Interventions
PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
Group III: Phase 2 (Arm 2)Active Control1 Intervention
Pembrolizumab (2 mg/kg every 3 weeks)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PV-10
2013
Completed Phase 1
~20
Pembrolizumab
2017
Completed Phase 3
~3130

Find a Location

Who is running the clinical trial?

Provectus Biopharmaceuticals, Inc.Lead Sponsor
4 Previous Clinical Trials
110 Total Patients Enrolled
2 Trials studying Melanoma
98 Patients Enrolled for Melanoma
Eric Wachter, Ph.D.Study DirectorProvectus Pharmaceuticals, Inc.
6 Previous Clinical Trials
196 Total Patients Enrolled
2 Trials studying Melanoma
40 Patients Enrolled for Melanoma

Media Library

Pembrolizumab (Checkpoint Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02557321 — Phase 1 & 2
Melanoma Research Study Groups: Phase 2 (Arm 2), Phase 1b, Phase 2 (Arm 1)
Melanoma Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT02557321 — Phase 1 & 2
Pembrolizumab (Checkpoint Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02557321 — Phase 1 & 2
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top